+44 (0) 1793 575 050
service@jointoperations.co.uk

Richard Forster, founder of Joint Operations has a long standing working relationship with Allosource and their sister company JRF. Together they have overseen the supply of their Allografts in the UK for a number of years.

 

This recent paper highlights a number of risk factors in ACL reconstruction; a key one being the graft preparation techniques used by different tissue banks. The excellent results of Allosource (AlloTrue & AlloWash) vs. RTI (BioCleanse) highlights some of the key reasons behind the growing success for Allosource, a not for profit organisation.

 

Allosource is one of the USA’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing. It has been announced that AlloSource’s tendons, processed using its proprietary AlloTrue™ cleansing process, as well as low-dose irradiation, are effective when used in anterior cruciate ligament reconstruction (ACLR).  The positive clinical results of the AlloSource tendons used in Kaiser Permanente’s ACL Revision Risks study were presented at last year’s American Academy of Orthopedic Surgeons (AAOS) Annual Meeting in Las Vegas.

 

Kaiser Permanente’s retrospective study and associated paper titled Revision Risk After Allograft Anterior Cruciate Ligament Reconstruction: Graft and Patient Associations is the largest known study of its kind.  The study was conducted on 5,968 primary ACLR cases, using allografts processed with varied techniques such as irradiation doses, AlloWash, AlloTrue and BioCleanse.  The median age of the patients at the time of surgery was 34.1-years-old and 61.8 percent of the patients were male.

 

The study results found BioCleanse graft processing, younger patient age, BPTB allografts and irradiation over 1.8 Mrad were all associated with a higher risk of clinical failure and subsequent revision surgery.  AlloSource tendons are treated with irradiation doses between .95-1.4 Mrad.  Also, the use of AlloTrue did not significantly affect revision rate.

 

“Large scale studies like this are important to the medical community,” said Kimberly French, AlloSource Director of Marketing.  “Tissue banks use different processes to ensure the safety and quality of their tissue and these results are an example of the success AlloSource has had with AlloTrue.”

 

AlloSource’s AlloTrue™ technology is a unique, patented process designed to penetrate deep within donor tissue to remove blood and lipids and reduce bioburden.  Created through a collaboration of AlloSource’s engineering, research and development, and operations departments, AlloTrue utilizes a combination of antibiotic treatments, alcohol, peroxide (cut tissue only) and multiple water rinses. The deep penetrating cleansing, with minimal tissue manipulation, results in microbial inactivation.

 

For more information about AlloSource please click here.